

Project FIND AKKURE

About us

Akkure was launched in 2019 with the goal to revolutionise the clinical trials industry by developing a new way to find precision clinical trials using AI and Genomics. Partnering with the Royal College of Surgeons (FutureNeuro) & Microsoft, AKKURE was awarded funding for the €6 million project through the government's Disruptive Technology Innovation Fund (DTIF).

What is Project "FIND AKKURE" ?

AKKURE envisions a major opportunity for patients & communities to set the agenda for the future advancement of the scientific understanding of diseases and conditions that matter to them.

Project "FIND AKKURE" will allow people to collectivise their precision health data through the creation of cohorts of condition based groups by digitising their DNA, through the creation of their own "Medical Digital Twin", the architecture of which, will ensure ownership, control and reward remains fully with the patients.

We are asking individuals to register their interest in diseases and conditions that matter to them to create communities of "Medical Digital Twins".

Akkure will then partner with prospective researchers on behalf of these digital communities to analyse the insights contained in these "Medical Digital Twins" to be used in a scientific sandbox to support the development of novel therapeutics and new medical technologies.

What is a Medical Digital Twin?

Medical Digital Twins represent virtual copies of a person's entire genetic makeup fused with their individual clinical health. Digital Twins are a powerful asset that can be used as control arms in studies and as a source of data for new personalised therapeutics.

Digital Twins are created through machine learning models, designed to possess the same baseline precision medical data as their organic human counterparts. It's a transformative way to 'translate carbon life to silicon-based assets' and empower the future of clinical trials and new drugs.

In-Silico Drug development

In-Silico trials use computational models to simulate how a drug or intervention will affect a virtual population. The technology is emerging as a way to cut costs and accelerate timelines for clinical trials while reducing the risk to animal or human test subjects.

Using statistical models of disease progression, researchers can better simulate clinical outcomes for a given cohort of patients, down to the level of how specific traits impact treatment. This will result in a hyper-personalized approach to assessing a patient's fit for a given intervention and allow for the creation of individualised targeted therapeutics.

How are we making it happen?

We're building a library of physiological, genomic, and clinical data via the creation of Medical Digital twins, combined with an innovative operating system, leveraging blockchain and NLP technology, for data accessibility and patient ownership and control.

Through our interactive analytical and machine learning platform, we are empowering pharmaceutical companies worldwide to accelerate new therapeutics by capturing population level, clinically matched genomic data, thus enabling the next generation of clinical trials.

Who are we Targeting?

Based on our current partnerships our initial focus is on cancer and neurological conditions as this is where we see the most urgent and unmet needs.

Our founders have an intimate awareness of the profound damaging impact of neurological and cancer diseases along with the lack of progress in creating any meaningful therapy let alone cure.

There is a better way.

The convergence of enabling technologies in the form of Genomics and AI-based machine learning will provide new insights into targets for personalised and cohort based therapeutics.

For this, we need your help to create powerful communities of Medical Digital Twins.